SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

Read more breaking news

 

 
News in brief

Cerveau tapped for Alzheimer's research

Melissa Fassbender

By Melissa Fassbender

07-Mar-2017

Cerveau tapped for Alzheimer's research

Cerveau has signed a research agreement through which it will supply its early-stage imaging agent to assess the stages of Alzheimer’s disease and other neurodegenerative diseases.

Cerveau Technologies, Inc. will support various research projects as part of the clinical research agreement with the NIH-funded University of Wisconsin-Madison Alzheimer’s Disease Research Center (ADRC)

The agreement specifically incudes access to the company’s imaging agent, MK-6240, which it licensed from Merk & CO Inc (MSD) in January of this year.

The agent will be used in Positron Emission Tomography (PET) scans to evaluate the progression of neurofibrillary tangles (NFTs) in the brain.

Dr. Sterling Johnson, Associate Director of the Wisconsin Alzheimer’s Disease Research Center commented in a release that the collaborative tau imaging research program will provide “valuable information about the rates of progression across the Alzheimer’s Disease stages from preclinical to overt dementia.”

(Feature image: iStock/semakokal)

Related suppliers

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...